Trial Profile
An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients With Neovascular Age-Related Macular Degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jun 2018
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms RE-VIEW
- Sponsors Regeneron Pharmaceuticals
- 01 May 2018 Results (n=154) assessing efficacy, safety and tolerability of intravitreal aflibercept injection in patients with neovascular Age-Related Macular Degeneration, were published in the Cornea.
- 12 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 29 Apr 2015 New trial record